

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 July 2008 (31.07.2008)

PCT

(10) International Publication Number
WO 2008/090429 A1

(51) International Patent Classification:

A61K 31/40 (2006.01) A61P 25/16 (2006.01)
A61P 25/18 (2006.01) C07D 295/155 (2006.01)

(74) Agents: FULLER, Grover, F., Jr. et al.; Pfizer Inc., 150 East 42nd Street, New York, New York 10017 (US).

(21) International Application Number:

PCT/IB2008/000088

(22) International Filing Date: 10 January 2008 (10.01.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/885,931 22 January 2007 (22.01.2007) US

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(71) Applicant (for all designated States except US): **PFIZER PRODUCTS INC.** [US/US]; Eastern Point Road, Groton, Connecticut 06340 (US).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **WAGER, Travis, T.** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, Connecticut 06340 (US). **BUTLER, Todd, William** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, Connecticut 06340 (US).

Published:

— with international search report

(54) Title: TOSYLATE SALT OF A THERAPEUTIC COMPOUND AND PHARMACEUTICAL COMPOSITIONS THEREOF




FIG. 1

(57) Abstract: The present invention is directed to the tosylate salt of *trans*-N-ethyl-3- fluoro-3-[3-fluoro-4-(pyrrolidin-1-yl-methyl)-phenyl]-cyclobutanecarboxamide Formula (I):to solvates (e.g., hydrates) thereof, to polymorphs thereof, to pharmaceutical compositions thereof and to a method of treating depression, mood disorders, schizophrenia, anxiety disorders, cognitive disorders, Alzheimer's disease, attention-deficit disorder (ADD), attention-deficit hyperactivity disorder (ADHD), psychotic disorders, sleep disorders, obesity, dizziness, epilepsy, motion sickness, respiratory diseases, allergy, allergy-induced airway responses, allergic rhinitis, nasal congestion, allergic congestion, congestion, hypotension, cardiovascular disease, diseases of the GI tract, hyper- and hypo-motility and acidic secretion of the gastro-intestinal tract comprising administering a therapeutically effective amount thereof.

WO 2008/090429 A1